Summary
Boston Scientific Corporation (BSX) filed an 8-K on February 26, 2007, detailing significant changes to executive compensation and retention agreements. The Compensation Committee approved an amendment to the definition of 'Change in Control' within executive retention agreements, shifting the trigger from shareholder approval to the actual consummation of a reorganization, merger, consolidation, or similar transaction. This provides greater clarity and certainty regarding the conditions under which these agreements become active for executive officers. Additionally, the company approved an amendment to its 2007 Performance Incentive Plan, introducing an incentive compensation recoupment policy. This policy ensures that if the company's financial statements are restated and would result in a reduction of a previously awarded incentive payment, the company can seek reimbursement from executive officers for any excess amounts paid based on the original, un-restated financials. These changes reflect a proactive approach to corporate governance and executive accountability.
Key Highlights
- 1Amendment to 'Change in Control' definition in executive retention agreements, now triggered by consummation of transaction rather than shareholder approval.
- 2Introduction of an incentive compensation recoupment policy within the 2007 Performance Incentive Plan.
- 3The recoupment policy allows the company to seek reimbursement if financial restatements reduce previously paid incentive awards.
- 4These changes apply to executive officers of Boston Scientific Corporation.
- 5The Compensation Committee of the Board of Directors approved these amendments.
- 6The filing includes the amended form of Retention Agreement and the amended 2007 Performance Incentive Plan as exhibits.